ATE124457T1 - Hemmung der viralen replikation. - Google Patents

Hemmung der viralen replikation.

Info

Publication number
ATE124457T1
ATE124457T1 AT91919581T AT91919581T ATE124457T1 AT E124457 T1 ATE124457 T1 AT E124457T1 AT 91919581 T AT91919581 T AT 91919581T AT 91919581 T AT91919581 T AT 91919581T AT E124457 T1 ATE124457 T1 AT E124457T1
Authority
AT
Austria
Prior art keywords
inhibition
viral replication
dna
cell
viral
Prior art date
Application number
AT91919581T
Other languages
English (en)
Inventor
Michael J Scolaro
Sean M Sullivan
Original Assignee
Vestar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vestar Inc filed Critical Vestar Inc
Application granted granted Critical
Publication of ATE124457T1 publication Critical patent/ATE124457T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • AIDS & HIV (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT91919581T 1990-10-09 1991-10-09 Hemmung der viralen replikation. ATE124457T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59525390A 1990-10-09 1990-10-09

Publications (1)

Publication Number Publication Date
ATE124457T1 true ATE124457T1 (de) 1995-07-15

Family

ID=24382446

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91919581T ATE124457T1 (de) 1990-10-09 1991-10-09 Hemmung der viralen replikation.

Country Status (9)

Country Link
EP (1) EP0552280B1 (de)
JP (1) JPH06504429A (de)
AT (1) ATE124457T1 (de)
AU (1) AU652006B2 (de)
CA (1) CA2093816A1 (de)
DE (1) DE69110897T2 (de)
DK (1) DK0552280T3 (de)
ES (1) ES2073777T3 (de)
WO (1) WO1992006192A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3351476B2 (ja) * 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
WO1995016437A1 (en) * 1993-12-17 1995-06-22 Micro-Pak, Inc. Method of transmitting a biologically active material to a cell
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
JP4259611B2 (ja) 1994-08-29 2009-04-30 ウェイク フォレスト ユニバーシティ ウィルス感染を治療するための脂質アナログ
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
KR100871648B1 (ko) 2001-08-31 2008-12-03 톰슨 라이센싱 조건부 액세스 시스템을 구현하는 방법, 컨텐트를 전송하는 방법 및 그 장치 및 컨텐트를 수신하고 처리하는 방법 및 그 장치
DE602004030923D1 (de) * 2003-09-17 2011-02-17 Rodos Biotarget Gmbh Lipid-arzneimittel-formulierungen zur gezielten pharmakotherapie von myeloiden und lymphoiden immunzellen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853139T2 (de) * 1987-06-26 1995-06-14 Syntro Corp Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung.
DE3742049A1 (de) * 1987-12-11 1989-06-22 Theurer Karl Eugen Herstellung und anwendung von impfstoffen und diagnostika fuer virus- und krebserkrankungen
JPH04501052A (ja) * 1988-02-26 1992-02-27 ザ・ウスター・フアウンデーシヨン・フオー・バイオメデイカル・リサーチ 外来性オリゴヌクレオチドによるｈｔｌｖ―３の抑制

Also Published As

Publication number Publication date
JPH06504429A (ja) 1994-05-26
DE69110897T2 (de) 1995-11-30
DK0552280T3 (da) 1995-08-28
AU652006B2 (en) 1994-08-11
ES2073777T3 (es) 1995-08-16
CA2093816A1 (en) 1992-04-10
EP0552280B1 (de) 1995-06-28
AU8875991A (en) 1992-04-28
DE69110897D1 (de) 1995-08-03
EP0552280A1 (de) 1993-07-28
WO1992006192A1 (en) 1992-04-16

Similar Documents

Publication Publication Date Title
DE69819167D1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
DE69535125D1 (de) Impstoff gegen felines immunodefizienz-virus
ATE273320T1 (de) Fusogene liposomen
DE69532369D1 (de) Rekombinantes infektiöses nicht-in-Segmente-geteiltes, negativ-Strange-RNS-Virus
ATE420190T1 (de) Rekombinanter lebendimpfstoff, der katzenherpesvirus typ i enthält, insbesondere für die behandlung von infektiöser bauchfellentzündung bei katzen
ATE124457T1 (de) Hemmung der viralen replikation.
NO944245L (no) Rekombinante DNA-molekyler som koder for aminopeptidase-enzymer og deres anvendelse ved fremstilling av vaksiner mot helmintinfeksjoner
DK0958353T3 (da) Phytase polypeptider
CA2186044A1 (en) Novel mutated viruses, anti-viral compounds and novel methods of making vaccines
DK0599868T3 (da) Polyphenoloxidase-gener
DE68911297D1 (de) Heparin bindende proteine, dafür kodierende dna, verfahren zu ihrer herstellung sowie sie enthaltende therapeutische präparate.
PT778894E (pt) Vacina da peritonite infecciosa felina.
FI902803A7 (fi) DNA-sekvenssi, joka koodaa a-amylaasi-pullulanaasientsyymiä
FI891049A0 (fi) En eller flera lockfoersedda oeppningar i arbetspaln, i synnerhet diskbaenk i koek.
ATE442441T1 (de) Virale expressionsvektoren für pflanzen
ES2367245T8 (es) Virus recombinante que expresa adn foráneo que codifica cd80 felino, cd28 felino, ctla-4felino o cd86 felino y usos del mismo.
ATE335507T1 (de) Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
DE69733948D1 (de) In vivo herstellung von replicativen molekülen
WO1998042847A3 (de) Papillomvirus-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung
IT1286307B1 (it) Virus mixomatoso ricombinante, suo impiego per la produzione di un vaccino e relativo vaccino.
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
WO2004027066A3 (fr) Protéine recombinante chimérique et diagnostic in vitro du hiv
WO2000042063A3 (de) Peptide zur inhibierung von hbv-core-proteinen
FI964784A0 (fi) Yhdistelmä-DNA-viruksia, valmistus ja käyttö geeniterapiassa
AU1557001A (en) Novel endoplasmic reticulum-localized protein, remedies containing the same for diseases associated with glycoprotein abnormality, dna encoding this protein andgene remedies containing the same for treating diseases associated with glycopr otein abnormality

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee